Browse
Submit Data
Databases
API
Help

Dataset Information

7 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A phase II study of TAS-102 plus Bevacizumab therapy for advanced/recurrent colorectal cancer with difficulty on intensive chemotherapy

ABSTRACT: Interventions: TAS-102 plus bevacizumab combination therapy (q4w) TAS-102: 35mg/m2 BID on days 1-5 and 8-12 Bevacizumab: 5mg/kg on day1 and 15 Primary outcome(s): Progression-free survival Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2637963 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

TAS-102 and Bevacizumab as third line chemotherapy for colorectal cancer. Phase 2 trial

Project description:Interventions: TAS-102: 35mg/m2 given orally twice daily on days 1-5 and 15-19 in a 28-day cycle. Bevacizumab: 5mg/kg given intravenously in a 2-week cycle Primary outcome(s): progression free survival Study Design: Single arm Non-randomized

| 2645202 | ecrin-mdr-crc

TAS-CC4 Study

| 2614211 | ecrin-mdr-crc

TAS-102 and Bevacizumab as salvage line chemotherapy for colorectal cancer

Project description:Interventions: TAS-102(35mg/m2) is administered orally twice daily in 1-5days and 15-20 days and Bevacizumab(5mg/kg) is administered by injection in day 1 and day15. 1 cycle is 28days. Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2646936 | ecrin-mdr-crc

Phase 2 trial of TAS-102 plus bevacizumab in patients with advanced/recurrent colorectal cancer who had previously received on oxaliplatin, irinotecan and fluoropyrimidine

Project description:Interventions: TAS-102(35mg/m2) is administered orally twice daily in 1-5days and 15-20 days and Bevacizumab(5mg/kg) is administered by injection in day 1 and day15. 1 cycle is 28days. Primary outcome(s): Disease control rate Study Design: Single arm Non-randomized

| 2641267 | ecrin-mdr-crc

TAS-102 and Bevacizumab as second line chemotherapy for colorectal cancer. Phase 2 trial

Project description:Interventions: TAS-102: 35mg/m2 given orally twice a day in a 28-day cycle, 2-week cycle of 5 days treatment followed by a 2-day rest period, and then a 14-day rest period Bevacizumab: 5mg/kg given intravenously in a 2-week cycle Primary outcome(s): progression free survival Study Design: Single arm Non-randomized

| 2637697 | ecrin-mdr-crc

TAS-102 and Bevacizumab as third line chemotherapy for colorectal cancer. Phase 2 trial

| 2637698 | ecrin-mdr-crc

TAS-102 plus Bevacizumab combination as salvage therapy in elderly patients with metastatic colorectal cancer, phase 2 trial

Project description:Interventions: TAS-102: 35mg/m2 given orally twice a day in a 28-day cycle, 2-week cycle of 5 days treatment followed by a 2-day rest period, and then a 14-day rest period Bevacizumab: 5mg/kg given intravenously in a 2-week cycle Primary outcome(s): overall survival Study Design: Single arm Non-randomized

| 2636928 | ecrin-mdr-crc

TAS-102 plus Bevacizumab combination as first-line treatment in elderly patients with metastatic colorectal cancer, phase 2 trial

Project description:Interventions: TAS-102: 35mg/m2 given orally twice a day in a 28-day cycle, 2-week cycle of 5 days treatment followed by a 2-day rest period, and then a 14-day rest period Bevacizumab: 5mg/kg given intravenously in a 2-week cycle Primary outcome(s): relative dose intensity Study Design: Single arm Non-randomized

| 2635519 | ecrin-mdr-crc

Multicenter Phase 1b/2 Trial of TAS-102 with Bevacizumab in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.

Project description:Interventions: 1 cycle is 28days. TAS-102(35mg/m2) is administered orally twice daily in 1-5days and 8-12 days and Bevacizumab(5mg/kg) is administered by injection in day 1 and day15. Primary outcome(s): 4 month progression free survival by central assessment( 4M PFS) Study Design: Single arm Non-randomized

| 2628236 | ecrin-mdr-crc

A phase II study of guadecitabien combined with irinotecan vs regorafenib or TAS-102 in previously treated metastatic colorectal cancer patients

Project description:A phase II study of guadecitabien combined with irinotecan vs regorafenib or TAS-102 in previously treated metastatic colorectal cancer patients

2023-03-31 | GSE226221 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data